DiaMedica Therapeutics (DMAC) Competitors $3.65 +0.08 (+2.24%) Closing price 07/3/2025 03:41 PM EasternExtended Trading$3.72 +0.07 (+2.03%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. SION, IOVA, CDXC, GHRS, EOLS, XNCR, KALV, AUTL, SANA, and SAGEShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Sionna Therapeutics (SION), Iovance Biotherapeutics (IOVA), ChromaDex (CDXC), GH Research (GHRS), Evolus (EOLS), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Autolus Therapeutics (AUTL), Sana Biotechnology (SANA), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors Sionna Therapeutics Iovance Biotherapeutics ChromaDex GH Research Evolus Xencor KalVista Pharmaceuticals Autolus Therapeutics Sana Biotechnology Sage Therapeutics Sionna Therapeutics (NASDAQ:SION) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Which has preferable earnings & valuation, SION or DMAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/ADiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-5.70 Do analysts rate SION or DMAC? Sionna Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 81.69%. DiaMedica Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 119.18%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SION or DMAC? In the previous week, Sionna Therapeutics had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Sionna Therapeutics and 1 mentions for DiaMedica Therapeutics. Sionna Therapeutics' average media sentiment score of 1.15 beat DiaMedica Therapeutics' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SION or DMAC more profitable? Sionna Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A DiaMedica Therapeutics N/A -61.35%-55.53% Do insiders & institutionals hold more shares of SION or DMAC? 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 3.9% of Sionna Therapeutics shares are owned by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySionna Therapeutics beats DiaMedica Therapeutics on 5 of the 9 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.24M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-5.7021.5627.4320.22Price / SalesN/A281.76416.87118.64Price / CashN/A42.7336.8958.07Price / Book3.847.518.035.67Net Income-$24.44M-$55.05M$3.18B$249.13M7 Day Performance-4.95%4.61%2.88%3.28%1 Month Performance-10.76%4.72%3.69%5.56%1 Year Performance25.86%5.92%36.02%21.12% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics0.9063 of 5 stars$3.65+2.2%$8.00+119.2%+26.3%$161.24MN/A-5.7020SIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$622.15MN/A0.0035Positive NewsInsider TradeIOVAIovance Biotherapeutics4.709 of 5 stars$1.85-6.6%$12.22+560.7%-76.3%$617.77M$164.07M-1.49500CDXCChromaDex3.2254 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120GHRSGH Research2.0723 of 5 stars$11.68-5.1%$32.00+174.0%+23.7%$607.71MN/A-14.7810Analyst UpgradeEOLSEvolus3.6065 of 5 stars$9.38+1.1%$23.75+153.2%-15.7%$604.82M$266.27M-10.54170Positive NewsXNCRXencor4.0329 of 5 stars$8.41-1.5%$28.00+232.9%-54.8%$598.54M$110.49M-2.75280Positive NewsKALVKalVista Pharmaceuticals4.1757 of 5 stars$11.93-1.8%$24.83+108.2%+1.5%$593.16MN/A-3.21100Upcoming EarningsAUTLAutolus Therapeutics2.5559 of 5 stars$2.21+7.8%$9.32+321.7%-32.1%$588.17M$9.01M-2.51330Positive NewsSANASana Biotechnology2.7849 of 5 stars$2.60-0.4%$10.80+315.4%-38.8%$586.25MN/A-2.95380Analyst ForecastGap UpHigh Trading VolumeSAGESage Therapeutics3.2437 of 5 stars$9.30flat$8.93-3.9%-13.4%$582.37M$41.24M-1.60690 Related Companies and Tools Related Companies Sionna Therapeutics Alternatives Iovance Biotherapeutics Alternatives ChromaDex Alternatives GH Research Alternatives Evolus Alternatives Xencor Alternatives KalVista Pharmaceuticals Alternatives Autolus Therapeutics Alternatives Sana Biotechnology Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
